Lactoferrin Blocks SARS Pseudovirus Entry into Cells
Author Information
Author(s): Lang Jianshe, Yang Ning, Deng Jiejie, Liu Kangtai, Yang Peng, Zhang Guigen, Jiang Chengyu
Primary Institution: State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Peking Union Medical College, Tsinghua University, Beijing, People's Republic of China
Hypothesis
Lactoferrin may inhibit SARS-CoV infection by binding to heparan sulfate proteoglycans on host cells.
Conclusion
Lactoferrin inhibits SARS pseudovirus infection by blocking the binding of the spike protein to host cells through interactions with heparan sulfate proteoglycans.
Supporting Evidence
- Lactoferrin was shown to inhibit SARS pseudovirus infection in a dose-dependent manner.
- The study confirmed that lactoferrin binds to heparan sulfate proteoglycans on the cell surface.
- Heparin treatment reduced the binding of lactoferrin to cells, indicating its role in the inhibition mechanism.
- Lactoferrin did not disrupt the interaction between spike protein and ACE2, suggesting an alternative binding mechanism.
Takeaway
Lactoferrin helps protect against a virus called SARS by sticking to the virus's entry points on cells, stopping it from getting in.
Methodology
The study used HEK293E/ACE2-Myc cells to test the effect of lactoferrin on SARS pseudovirus entry through various assays including flow cytometry and western blotting.
Limitations
The study primarily focused on in vitro experiments, which may not fully represent in vivo conditions.
Statistical Information
P-Value
0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website